ClinicalTrials.gg
CompletedNCT04909242Updated Jun 2, 2022

Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants

A Phase 1 interventional study of DZD9008 and Placebo in Healthy Volunteers, sponsored by Dizal Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-02.

Sponsored by Dizal Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2022, 4 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a Phase 1, randomised, double-blind, placebo-controlled, single ascending dose sequential group study in healthy participants. This study consists of three parts: Part A (single dose escalation, SAD) , Part B (food effect, FE) and Part C (relative bioavailability, BA).

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Dizal Pharmaceuticals is the lead sponsor of 39 studies on the registry; 15 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be able to understand the nature of the trial and provide a signed and dated, written form before any study-specific procedures, sampling and analyses.
  • Provision of signed and dated written Optional Genetic Research informed consent prior to collection of samples for optional genetic research.
  • Healthy male or female participants aged 18 to 60 years (inclusive), with 18.0 to 30.0 kg/m2 (inclusive). Body weight: ≥ 55 kg for male, ≥ 45 kg for female.
  • Healthy participants defined as the absence of acute or chronic deviations from normal in medical history, physical examination, visual assessment, (ECG), and clinical laboratory determinations at screening.
  • Participants must agree to practice effective .
  • Normal baseline PFTs (≥ 80% predicted normal for spirometry, lung volumes).
  • Normal baseline ECG ( \< 450 msec, PR \< 210 msec).
  • Non-smoker (not smoked within 3 months).
  • Liver biochemistry parameters: (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × (ULN); Total ≤ 1.5 × ULN
  • Adequate organ function including hepatic, renal, cardiac, visual and bone marrow function as determined by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Ongoing or prior pulmonary disease including asthma, , interstitial lung disease and pneumonitis including but not limited to drug-related pneumonitis.
  • Women who are breast feeding.
  • Positive pregnancy test prior to study entry.
  • History of of any type, with the exception of the following: surgically excised non-melanomatous skin cancers more than 5 years prior to receiving IP.
  • A history of additional risk factors for TdP (e.g. heart failure, hypokalemia, family history of Long syndrome).
  • No prior history of atrial fibrillation within 6 months prior to first dosing of DZD9008
  • Manifestations of malabsorption due to prior GI surgery, GI disease, or for an unknown other reason that may affect the absorption of DZD9008-. Pulmonary infections or other active infection within 30 days of
  • History of bleeding disorder (including hemophilia, Von Willebrand disease, etc), history of stroke or intracranial haemorrhage within 6 months before study drug administration.
  • Judgement by the investigator that the participant is not likely to comply with study procedures, restrictions and requirements.
  • Positive serology or a known history of virus (HBV), virus (HCV), .
  • Resting blood pressure > 140/90 mmHg at screening .
  • Resting pulse rate \< 45 beats per minute.
  • History of severe allergy or reaction or ongoing allergy or hypersensitivity reaction, as judged by investigator, or history of hypersensitivity to EGFR//BTK inhibitors.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    single oral dose of DZD9008

    single dose of DZD9008 (50 mg, 100 mg, 200 mg, 300 mg and 400 mg, tablet)

    Drug: DZD9008

  • Placebo comparator
    single oral dose of placebo

    single dose of placebo (matching placebo, 50 mg, 100 mg, 200 mg, 300 mg and 400 mg, tablet)

    Drug: Placebo

  • Experimental
    single oral dose of DZD9008 (300 mg, tablet)

    Drug: DZD9008

  • Experimental
    single oral dose of DZD9008 (100 mg, tablet or suspension)

    Drug: DZD9008

Interventions

  • In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive DZD9008 at different dose levels. There are 5 planned dose cohorts, starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008 or matching placebo, namely 100 mg, 200 mg, 300 mg and 400 mg.

  • DrugPlacebo

    In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive matching placebo for DZD9008 at different dose levels. There are 5 planned dose cohorts of matching placebo for DZD9008, starting from 50 mg once daily.

  • In Part C, healthy adult participants will be enrolled to receive a single dose of DZD9008 as suspension in period 1 and as tablet in period 2.

  • Healthy adult participants will be randomized to receive DZD9008 single dose at a defined dose under a cross-over condition with or without food (low-fat in Part B; high-fat in Part D).

06

What researchers measure

Primary outcomes

  1. Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs)

    To assess the safety and tolerability of DZD9008 following oral administration of single ascending doses in healthy adult participants.

    Time frame: up to 14 days after study drug administration

  2. Number of participants with clinically significant laboratory assessment abnormalities

    To assess the safety and tolerability of DZD9008 following oral administration of single ascending doses in healthy adult participants.

    Time frame: up to 14 days after study drug administration

  3. Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities

    To assess the safety and tolerability of DZD9008 following oral administration of single ascending doses in healthy adult participants.

    Time frame: up to 14 days after study drug administration

  4. Number of participants with clinically significant abnormalities in LVEF

    To assess the safety and tolerability of DZD9008 following oral administration of single ascending doses in healthy adult participants.

    Time frame: up to 14 days after study drug administration

  5. Number of participants with clinically significant abnormalities in FEV1%

    To assess the safety and tolerability of DZD9008 following oral administration of single ascending doses in healthy adult participants.

    Time frame: up to 14 days after study drug administration

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of DZD9008

    Time frame: up to 10 days after study drug administration

  2. Time to reach maximum plasma concentration (tmax)

    Time frame: up to 10 days after study drug administration

  3. Area under the concentration-time curve from time 0 (pre-dose) to the time of the dosing interval (AUC0-t)

    Time frame: up to 10 days after study drug administration

  4. Area under the concentration-time curve from time 0 to infinity (AUC0-inf)

    Time frame: up to 10 days after study drug administration

  5. Apparent total plasma clearance (CL/F)

    Time frame: up to 10 days after study drug administration

  6. Apparent volume of distribution (Vz/F)

    Time frame: up to 10 days after study drug administration

  7. Mean residence time (MRT)

    Time frame: up to 10 days after study drug administration

  8. Terminal elimination half-life (t1/2)

    Time frame: up to 10 days after study drug administration

07

Study locations

1 site
  • PRA Health Sciences
    Lenexa, Kansas 66219, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Feb 2022, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2021
First posted
Jun 1, 2021
StartActual
Apr 21, 2021
Primary completionActual
Feb 7, 2022
CompletionActual
Feb 7, 2022
Last update
Jun 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04909242
Responsible party
Sponsor
First posted
Jun 1, 2021
Start date
Apr 21, 2021
Primary completion
Feb 7, 2022
Completion
Feb 7, 2022
Last update
Jun 2, 2022

Study contacts

Daniel Dickerson
principal investigator · PRA Health Sciences

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sunvozertinib

Start the discussion